Evaluation of miRNA Expression in Patients with Gestational Diabetes Mellitus: Investigating Diagnostic Potential and Clinical Implications
Mateusz Kunysz,Marek Cieśla,Dorota Darmochwał-Kolarz
DOI: https://doi.org/10.2147/dmso.s443755
2024-02-23
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Mateusz Kunysz, 1 Marek Cie&sacutela, 2 Dorota Darmochwa&lstrok-Kolarz 1 1 Department of Obstetrics & Gynecology, Institute of Medical Sciences, College of Medical Sciences, University of Rzeszow, Rzeszow, 35-959, Poland; 2 College of Medical Sciences, University of Rzeszow, Rzeszow, 35-959, Poland Correspondence: Mateusz Kunysz, Email Purpose: Gestational diabetes mellitus (GDM) is common pregnancy complication (8%), characterized by hyperglycemia resulting from pathological homeostatic mechanisms. There's a concerning trend of increasing GDM prevalence. New markers, particularly epigenetic ones, are sought for early detection and enhanced care. miRNA are small non-coding RNA molecules. The main goal was to investigate the potential role of miRNA (miR-16-5p, miR-222-3p, miR-21-5p) in GDM and their association with clinical features. Patients and Methods: The study included 72 pregnant patients, with 42 having GDM and 30 in the control group. miRNA expression was measured using ELISA. Results: There were no significant differences in miR-222-3p expression between GDM patients and the control group. The GDM group exhibited a positive correlation between miR-16-5p expression and miR-21-5p expression as well as between miR-16-5p expression and insulin resistance. In the GDM group, a positive correlation was observed between miR-21-5p expression and fasting glucose levels. Conclusion: Results do not confirm the role of miR-222-3p in GDM pathogenesis or as a diagnostic marker. Additionally, a role for miR-16-5p in GDM pathogenesis was observed. Furthermore, a potential role for miR-21-5p in monitoring GDM treatment is indicated. Keywords: gestational diabetes mellitus, miRNA, epigenetics, miR-16-5p, miR-222-3p, miR-21-5p Gestational diabetes mellitus (GDM) is the most commonly occurring complication in pregnancy characterized by hyperglycemia resulting from pathological homeostatic mechanisms; it is estimated to affect around 5.7% of pregnant women. 1,2 The World Health Organization (WHO) recommends conducting a screening glucose tolerance test (75g) for all pregnant women between the 24th and 28th week of pregnancy. It is also recommended to perform an early glucose tolerance test for pregnant women with risk factors such as obesity (BMI over 30 kg/m2), a history of GDM, pre-diabetes, HbA1c of 5.7%, polycystic ovary syndrome, first-degree relative with diabetes, pre-existing hypertension, or a history of delivering a baby weighing over 4000g in a previous pregnancy. 2,3 Known risk factors for increased occurrence of diabetes include advanced maternal age, overweight and obesity especially before pregnancy, excessive weight gain during pregnancy, lack of physical activity, poor diet, race, and family history. 4 Additional risk factors include a history of intrauterine death, hypertension, and giving birth to a child with a developmental defect. If GDM is not accurately diagnosed and properly treated, it can lead to negative consequences during pregnancy for both the mother and the developing fetus. 5–8 Maternal complications may include an increased risk of cesarean section, peripartum trauma, and postpartum hemorrhage. Pregnant women with GDM also have an increased risk of developing preeclampsia or pregnancy-induced hypertension. 7 Fetal complications depend on the duration of exposure. In the first trimester, hyperglycemia largely affects organogenesis and is responsible for spontaneous miscarriages and congenital malformations. In the second and third trimesters, the fetus is exposed to excessive growth and future metabolic burden, as well as systemic immaturity after birth. This can lead to peripartum trauma, chronic hypoxia, and even intrauterine death. 9 Far-reaching effects are observed in adult life, where maternal programming and hyperglycemia during pregnancy influence the risk of metabolic syndrome as well as eating disorders and glucose tolerance. 10,11 Epigenetic regulatory mechanisms in diabetes are divided into DNA methylation, histone modifications, and non-coding RNA (ncRNA). Non-coding RNA, which are not transcribed into proteins, constitute a significant part of RNA in cells (95–98%). Among ncRNA are molecules such as transfer RNA (tRNA) and ribosomal RNA (rRNA), as well as functionally significant RNA such as long ncRNA and microRNA (miRNA). 12 miRNA are small non-coding RNA molecules, first described in the Caenorhabditis elegans organism. 13 These genes encoding molecules usually occur in clusters and consist of about 20 nucleotides. Their main function is to regulate gene expression, both in terms of inhibition and stimulation. Inhibition of gene expres -Abstract Truncated-
endocrinology & metabolism